Industry News
Biotechnology Industry News

One of the most closely watched…
One of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.
Not content with navigating…
Not content with navigating Rezdiffra’s trajectory to blockbuster territory, Madrigal Pharmaceuticals has spent 2026 shopping for a range of drugs that the company hopes could work alongside its metabolic dysfunction-associated steatohepatitis trailblazer.
A phase 3 trial of Novo…
A phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify the company’s portfolio. Novo has chances to rescue
Apnimed has raised $192 million…
Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.
Following a pair of FDA rejections…
Following a pair of FDA rejections of its melanoma drug, Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of the candidate’s effectiveness.
Legend Biotech CEO Ying Huang,…
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on founding CEO
BMS may have been absent from the…
BMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.
Attovia Therapeutics, Braveheart…
Attovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their IPOs, positioning the trio to collectively net more than $500 million from public investors.
Takeda has dropped another celiac…
Takeda has dropped another celiac disease therapy from its phase 2 pipeline, leaving the company with just one shot at treating the condition.
Sanofi’s new CEO Belén Garijo…
Sanofi's new CEO Belén Garijo opened up for the first time about her strategy to reverse a trend of clinical setbacks, including dumping Regeneron-partnered IL-33 candidate itepekimab.
Johnson & Johnson is cruising…
Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.
A panel of experts today voted…
A panel of experts today voted against Capricor’s cell therapy for Duchenne muscular dystrophy, capping off an advisory committee meeting marked by statistical confusion.
After keeping tight-lipped for…
After keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the evidence.
Biogen’s business development team…
Biogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.
Novo Nordisk’s attempt to…
Novo Nordisk’s attempt to dismiss a lawsuit about its CagriSema readout has failed, with the judge ruling that parts of the investors’ argument were strong enough for the case to proceed.
Processa Pharmaceuticals has made…
Processa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.
Caldera Therapeutics has struck a…
Caldera Therapeutics has struck a reverse merger with the publicly traded Synlogic and inked a $278 million financing deal, continuing the meteoric rise of the inflammatory bowel disease startup.
AbCellera’s T-cell engager…
AbCellera’s T-cell engager platform has reeled in a second client this summer, with Vertex paying $28 million upfront for a collaboration that will include autoimmune conditions.
Flush with GLP-1 cash and pipeline…
Flush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural Pipeline-to-Patient Productivity Index, which evaluated 25 large, global biopharma companies on R&D productivity, market access
Incyte has ditched a JAK2…
Incyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.

